


This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

(D)- AND (L)-CYCLOHEXENYL-G, A NEW CLASS OF ANTIVIRAL AGENTS: SYNTHESIS, CONFORMATIONAL ANALYSIS, MOLECULAR MODELING, AND BIOLOGICAL ACTIVITY

J. Wang^a; M. Froeyen^a; C. Hendrix^a; C. Andrei^a; R. Snoeck^a; E. Lescrinier^a; E. De Clercq^a; P. Herdewijn^a

^a Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

Online publication date: 31 March 2001

To cite this Article Wang, J. , Froeyen, M. , Hendrix, C. , Andrei, C. , Snoeck, R. , Lescrinier, E. , De Clercq, E. and Herdewijn, P.(2001) '(D)- AND (L)-CYCLOHEXENYL-G, A NEW CLASS OF ANTIVIRAL AGENTS: SYNTHESIS, CONFORMATIONAL ANALYSIS, MOLECULAR MODELING, AND BIOLOGICAL ACTIVITY', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 727 – 730

To link to this Article: DOI: 10.1081/NCN-100002360

URL: <http://dx.doi.org/10.1081/NCN-100002360>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**(D)- AND (L)-CYCLOHEXENYL-G, A NEW CLASS
OF ANTIVIRAL AGENTS: SYNTHESIS,
CONFORMATIONAL ANALYSIS, MOLECULAR
MODELING, AND BIOLOGICAL ACTIVITY**

**J. Wang, M. Froeyen, C. Hendrix, C. Andrei, R. Snoeck,
E. Lescrinier, E. De Clercq, and P. Herdewijn***


Rega Institute for Medical Research, Katholieke Universiteit Leuven,
Minderbroedersstraat 10, B-3000 Leuven, Belgium

ABSTRACT

(D)- and (L)-cyclohexenyl-G were synthesized enantioselectively starting from (*R*)-carvone. Both show potent and selective anti-herpesvirus activity (HSV-1, HSV-2, VZV, CMV). Molecular modeling demonstrates that both isomers are bound in the active site of HSV-1 thymidine kinase in a high-energy conformation with the base moiety orienting in an equatorial position. It is believed that the flexibility of the cyclohexene ring is essential for their antiviral activity.

The development of novel nucleoside analogues as potential antiviral agents continues to attract considerable attention. Better understanding of the structure-activity relationship has provided information and criteria for a more rational design of new drugs. Based on our previous studies, it has been claimed that the conformational behavior of a nucleoside plays an important role in its biological activity. For example, the hexitol nucleosides, which show antiviral activity, in solution as well as in the solid state adopt a 3'-*endo* conformation (northern type) with the base moiety in an axial position. Co-crystallization of an antiviral anhydrohexitol nucleoside with herpes simplex virus (HSV) type 1 thymidine kinase showed a conformational inversion when the nucleoside analogue was bound in the active site (i.e. 2'-*endo*

*Corresponding author.



Scheme 1.

conformation with an equatorial base moiety) (1). This suggests that nucleosides can undergo conformational alteration during binding to herpesvirus thymidine kinase. This led us to assume that the conformational flexibility is important for the antiviral activity of a nucleoside.

Cyclohexene nucleosides are a class of six-membered carbocyclic nucleosides in which a double bond replaces the ring oxygen atom of a natural nucleoside. The resulting $\pi \rightarrow \sigma_{C1'-N}^*$ interaction mimics the anomeric effect of a natural nucleoside and considerably reduces the energy difference among the different conformers. These nucleosides are therefore conformationally more flexible to meet different enzymatic requirements.

The enantioselective synthesis of both (D)- and (L)-cyclohexene guanines **1**, using R-(–)-carvone as starting material, is shown in Scheme 1 (2–4). Carvone was converted into intermediate **3a,b** according to the reported procedure (5). Depending on the nature of the protection groups R_1 – R_4 , intermediate **3** allows for the synthesis of both (D)-**1** and (L)-**1**.


For the synthesis of (L)-**1**, the two free hydroxyl groups of **3a** were protected as a benzoate, the TBS group (R_2) was chemoselectively removed by treatment with 1 equiv. of TBAF, and the generated alcohol was converted into mesylate **4**. Removal of the remaining TBS group and eliminative oxidation gave rise to enone **5**. Reduction using NaBH_4 in the presence of $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ afforded the α -enol **6** ready for base moiety introduction. Treatment of **6** with 2-amino-6-chloropurine under Mitsunobu reaction conditions and conversion of the resulting 6-chloropurine compound into the guanine derivative gave (L)-**1**, after final deprotection under basic conditions.

The synthesis of (D)-**1** was carried out in a similar way. Enone **8** was obtained by mesylation of **3b** and deprotection of the Bn group, followed by oxidative elimination. Selective reduction and introduction of the base moiety was carried out according to the same procedure as used for (L)-**1**. Conversion of the 6-chloroguanine into guanine using $\text{TFA}/\text{H}_2\text{O}$ (3:1) resulted in simultaneous deprotection of the two TBS groups, affording directly (D)-**1**.

Both enantiomers show potent and selective anti-herpesvirus activity (HSV-1, HSV-2, VZV, CMV) (3). The activity spectrum of both compounds is very similar. They display the same activity against HSV-1 and HSV-2. Against VZV and CMV the potency of (L)-**1** is two-fold lower than that of (D)-**1**. They are as active as acyclovir and brivudin against HSV-1 and their activity is similar to that of

(D)- AND (L)-CYCLOHEXENYL-G

729



acyclovir against HSV-2. (D)-**1** shows the same potency against CMV as ganciclovir. (D)-**1** as well as (L)-**1** didn't show toxicity in four different cell lines (HeLa, Vero, E₆Sm, HEL).

Both compounds showed a reduced antiviral activity when evaluated against TK⁻ strains of HSV-1. This suggests that intracellular phosphorylation in the virus-infected cells is an important step for the enzymatic activation of these two nucleosides. Molecular modeling of (D)-**1** and (L)-**1** in complex with HSV-1 thymidine kinase showed that both compounds were bound in the active site in a high-energy conformation (²H₃ with pseudo-equatorial orientation of the base moiety in the syn conformation). This is in agreement with our previous observation that HSV-1 thymidine kinase may induce a conformational change of the nucleoside upon binding. The amino acids involved in binding of both isomers are the same, but their interaction energy is slightly different, mainly due to the hydrogen bonding interaction difference between the secondary hydroxyl group of the nucleosides with Glu-225. This energy difference might be relevant to their different biological activity.

Structural analysis demonstrates that the cyclohexene system is very flexible. This flexibility may be an important conformational characteristic explaining the potent antiviral activity of these cyclohexenyl nucleosides.

REFERENCES

1. Ostrowski, T.; Wroblowski, B.; Busson, R.; Rozenski, J.; De Clercq, E.; Bennett, M.S.; Champness, J.N.; Summers, W.C.; Sanderson, M.R.; Herdewijn, P. *J. Med. Chem.* **1998**, *41*, 4343–4353.
2. Wang, J.; Herdewijn, P. *Helv. Chim. Acta* **2000** (in press).
3. Wang, J.; Froeyen, M.; Hendrix, C.; Andrei, G.; Snoeck, R.; De Clercq, E.; Herdewijn, P. *J. Med. Chem.* **2000**, *43* (4), 736–745.
4. Wang, J.; Herdewijn, P. *J. Org. Chem.* **1999**, *64* (21), 7820–7827.
5. Wang, J.; Busson, R.; Blaton, N.; Rozenski, J.; Herdewijn, P. *J. Org. Chem.* **1998**, *63* (9), 3051–3058.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002360>